Objectives: Despite the continuing interest in health economic research, we could find no accessible data set on cost-effectiveness, useful as practical information to decision makers who must allocate scarce resources within the cardiovascular field. The aim of this paper was to present cost-effectiveness ratios, based on a systematic literature search for the treatment of heart diseases.
INTRODUCTION
Economic evaluations are used to inform decision makers about the efficient allocation of scarce health care resources, i.e. comparing value for money of alternative treatment strategies for a particular patient group. Moreover, economic evaluations provide a means of translating the relevant evidence into estimates of both costs and effects of the alternative treatment strategies being compared, drawing on evidence from a number of sources, rather than just the use of randomized controlled clinical trials. Economic evaluations may also be used to extrapolate end-points over an appropriate time horizon, often beyond the scope of a clinical trial.
Cost-effectiveness rankings or league tables provide a means of presenting results from economic evaluations and have been published both in North America and the UK [1, 2] . An extensive list of over five hundred cost-effectiveness ratios for life-saving interventions, including interventions for heart diseases, has also been presented by Tengs (1995) [3] .
Despite the continuing interest in cost-effectiveness, it is difficult to find both accessible and comprehensive data sets on costs and effects, useful as practical information for decision makers who must allocate scarce resources within the cardiovascular field. To this end, we compiled information from a systematic literature search in a cost-effectiveness ranking table for different heart conditions and treatment strategies expressed as a cost per quality adjusted life year (QALY) or life year (LY) gained. Presenting cost-effectiveness information in for example a cost-effectiveness ranking table constitutes a first step in making evidence accessible to decision makers. The aim of this paper was to present the results, based on a Eckard 4 systematic literature search for the treatment of heart diseases with regard to costeffectiveness.
Cost-effectiveness ratios
Cost-effectiveness results are often calculated in terms of cost per QALY or LY gained for one treatment strategy compared to another. The results are known as the incremental costeffectiveness ratios (ICERs), i.e. the ratio of the difference in health outcome (QALYs) between two alternatives; treatment A and treatment B. Thus, the ICER shows the mean incremental cost of gaining an extra QALY by employing the treatment A strategy compared to the treatment B strategy. A low ICER indicates greater cost-effectiveness compared to a higher ICER value.
ICER = (Cost A -Cost B) / (Effect A -Effect B)

MATERIAL AND METHODS
Systematic literature search
We conducted a comprehensive and extensive literature search on available economic analyses of intervention strategies within the cardiovascular field. The systematic literature search was conducted for the 2008 and updated version of the Swedish national guidelines for heart diseases [4] . The following databases were used to identify health economic analyses give additional hits, we did not include this database in the update.
The search term ´Heart Diseases´ was classified according to six disease groups; Coronary Artery Disease, Heart Failure, Arrhythmias, Heart Valve Disease, Inflammatory Heart Disease and Congenital Heart Disease and secondary prevention. Search terms referring to primary prevention were not covered in the literature search. Using a public health definition, primary prevention refers to intervention strategies aimed at preventing or postponing healthy individuals from getting ill, including lifestyle issues aimed at reducing risk factors due to for example smoking, obesity. Within each disease group, search terms were chosen in collaboration with a librarian. These search terms consist of diagnosis and standard medical treatment procedures reflecting the contents of each group respectively (Table I) . Medical Subject Headings (MeSH) were used as search terms in MEDLINE/PubMed when available and the search terms were extended with a free text search term when necessary.
Inclusion and exclusion criteria
After the initial database search, all abstracts were read and judged by two examiners.
Obvious irrelevant references were disregarded. Thereafter, the full references were acquired.
Each article was once again judged by two examiners working independently. A template was used to judge the quality of the cost-effectiveness analyses for data extraction. This was based on criteria generally accepted by the health economic community including; a description of a well-defined intervention strategy and a clearly defined comparator for a specific patient population. Information on study design, costs and effects (outcome) and discount rates were noted. Studies reporting the outcome measures as a cost per QALY or LY gained were included. Articles which met our inclusion criteria but could not be adapted to a Swedish setting and not included in the national guidelines were excluded. Articles were also excluded when they did not constitute an economic evaluation or did not have the right outcome measure (QALYs or LY gained). In a few cases, the treatment strategy was considered dominant though the outcome measures; QALY or LY, were not used. The health outcomes were considered the same or better than the alternative treatment strategy at a lower cost and were reported as dominant (<0) per event avoided in the Appendix tables. An intervention strategy is considered dominant, i.e. is said to dominate another, when its effectiveness is higher and its costs lower.
Compilation of results
The information compiled from the literature search was presented as a cost-effectiveness ranking table for different heart conditions and treatment strategies. The cost-effectiveness evidence compiled for the tables was adapted to a Swedish setting and complies with the 2008 version of the Swedish national guidelines. All included cost-effectiveness ratios prior to Eckard 7 2002 were used in the previous edition of the guidelines using the same methods for the literature search. The results were integrated in the current cost-effectiveness ranking table.
Using implantable cardioverter defibrillators (ICDs) for primary prevention as an example, we illustrate how cost-effectiveness evidence should be interpreted when there is a range of cost-effectiveness estimates for one single medical technology. The primary preventive use of implantable cardioverter defibrillators (ICDs) is aimed at patients with an already manifested cardiac disease for example heart failure with a risk of sudden cardiac death, i.e.
for patients not yet experiencing arrhythmia. ICDs may also be considered for patients with cardiac conditions such as long QT syndrome, hypertrophic cardiomyopathy and congenital heart disease.
The ICERs for the different treatment strategies were expressed as cost per QALY or LY gained by replacing one treatment strategy with another. All costs were adjusted to SEK using purchasing power parities (PPPs). The costs are in 2009 prices and have been converted to Euros using the average exchange rate of 1 Euro = 10.63 SEK.
RESULTS
More than a thousand abstracts were identified and read and over a hundred full bibliographical references were acquired and judged. Cost-effectiveness analyses which met our selection criteria gave sufficient information for more than two hundred cost-effectiveness ratio estimates. A hundred and thirty nine of these could be referred to Swedish treatment strategies used in the guidelines, ranging from dominant to those costing more than 1 000 000
Euros per QALY or LY gained.
The cost-effectiveness ranking table (Appendix) is separated into five sections according to the following; the first column contains the intervention strategy and the compared intervention and disease group, the second column contains patient population and possible sub-or risk group, the third column; ICERs presented as cost per QALY or LY gained. The fourth column includes information of the society from which the data originates, and the fifth column contains study references from which ICERs were drawn.
The table was categorized according to the disease group areas. The majority of ICERs refer to treatment strategies for coronary artery disease (acute coronary artery disease 63 (14) and stable angina 23 (10)), followed by arrhythmias 32 (10), heart failure 19 (7) and congenital heart disease 2 (1). Within each category there were several cost-effectiveness studies found referring to the same intervention strategy (referred to in parenthesis). For example, stable angina; twenty three cost-effectiveness ratios were found corresponding to ten different categories of interventions. Thus, instead of presenting one long list of cost-effectiveness ratios, each disease group constitutes its own cost-effectiveness ranking table and may be broken down even further if categorized for specific interventions.
When interpreting variations in ICERs for the same medical technology, different patient groups greatly affect the ICERs. Of the thirty two cost-effectiveness estimates provided for patients suffering from arrhythmias, there were several cost-effectiveness analyses relating to primary preventive use of ICDs in the cost-effectiveness ranking table.
[ Table IIa and IIb] [5] . Using different risks for sudden cardiac death thus gives important information in the guidance to decision makers and identifying high risk individuals would imply that the ICD treatment strategy would be costeffective compared to medical management. Table IIb presents how age and gender influence the ICERs of the ICD treatment strategy used for the prevention of sudden death in young people with inherited cardiac arrhythmias [6] . The ICER for any specific medical technology, may be categorized according to age, gender and other risk factors thus affecting the ICERs.
DISCUSSION
We have presented ICERs for the treatment of heart diseases based on an extensive systematic literature search. Available cost-effectiveness data represents an effort to amass costeffectiveness information presented in a cost-effectiveness ranking table for different heart conditions and treatment strategies. Though, most of the studies found were categorized within coronary artery disease, cost-effectiveness analyses covering a wide range of interventions strategies for the treatment of heart diseases were included.
The cost-effectiveness ranking table was not only compiled but also categorized according to disease group areas, summarized and broken down in order to convey as much information as possible to the reader in a simplified manner. Focusing on a single treatment strategy for patients with arrhythmias; implantable cardioverter defibrillators (ICDs), we have illustrated how cost-effectiveness information may be conveyed from cost-effectiveness ranking tables.
Presenting the ICERs for different risk groups (patient groups) may provide critical information to decision makers. Differentiating between patient groups, depending on low or high risk, gives important information, for example decision makers trying to optimize both the number of patients and which patients might benefit from a treatment.
Cost-effectiveness ranking tables provide a means of presenting cost-effectiveness evidence in terms of cost per QALY or LY gained. Using a generic outcome measure such as QALYs enables comparisons across different cost-effectiveness analyses. Both QALY and LY gained were included as outcome measures. The implication of this may be that the ICERs are overestimated as the outcome measure LY had not been adjusted. The cost-effectiveness analyses using LY as outcome measure were included in the rankling table when the analyses were judged to be of high quality and no other analyses using QALYs as outcome measure was found.
There are a number of methodological issues of importance when interpreting costeffectiveness rankings and comparing ICERs. The accuracy of the results presented in a costeffectiveness ranking table is always limited by the accuracy of data and assumptions upon which the original analysis were based, including the range of cost and consequences considered, the method for estimating utility values for health states, the discount rate used and the choice of comparator [7] . If a programme is to be considered cost-effective, depends on what we compare it to. The choice of comparison programme is probably the most important for the interpretation of ICERs [7] [8] [9] . They are to a large extent context specific [10] . Transferring results from one setting to the other (demography, availability of health care resources, relative prices etc.) may also constitute a problem, as different countries have different health systems, different perspectives for example use different discount rates [11] .
Another aspect of cost-effectiveness ranking tables is that they often use point-estimates giving a false sense of precision and rarely include measures of uncertainty for these estimates [12] . An alternative methodological approach would be to provide information on mean values as well as variance. Another way would be to use graphical framework such as the cost-effectiveness plane to present results [13] . A scatterplot diagram is a simple solution to illustrate the uncertainty in the results of cost-effectiveness analyses. Stochastic rankings have also been proposed to be used in a budgetary context [14] [15] [16] [17] [18] .
However, in the absence of systematic comparisons such as cost-effectiveness rankings, comparisons between health care programmes are likely to take place informally [19] .
Assembling data on a range of interventions gives greater prominence to cost-effectiveness data than does the reporting of cost-effectiveness studies individually [7, 8] . The type of evidence included in a cost-effectiveness ranking table is a condensed form of information. It constitutes a quality assessment and structured summary on economic evaluations and may be used as guide to navigate within the field of heart diseases and economic evaluations. This compilation of ICERs may also be used to identify areas which lack cost-effectiveness analyses.
Swedish national guidelines are produced using evidence-based knowledge for health care priority setting decisions. The decisions are based on the severity of the disease and clinical effectiveness as well as economic evidence, i.e. weighing different sources of evidence. Costeffectiveness evidence may therefore be viewed as part of the evidence-based knowledge used for decision-making. When the cost-effectiveness ratios are considered high or in controversial policy decision making cases the original studies have to be consulted and discussed further. In order to play a role in the decision-making process, cost-effectiveness evidence needs to be both accessed and accepted by the decision maker. Decision makers need evidence, both in a condensed and extensive form. However crude, cost-effectiveness ranking tables may provide valid information within a limited space, aiding decision makers on the allocation of health care resources [12] .
CONCLUSIONS
This paper represents a comprehensive and accessible compilation of health economic evidence for the treatment of heart diseases, useful in aiding health care decision-making when combined with supplementary information on the severity of the disease and clinical evidence.
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ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASA, Acetylsalicylic Acid (aspirin); BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; Dominant (<0), a treatment strategy associated with incremental gain in effects with reduced costs; EF, ejection fraction; ICD, implantable cardioverter defibrillator; ICER, incremental cost-effectiveness ratio; LQTS, long QT syndrome; LVEF, left ventricular ejection fraction; LY, life year; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; QALY, quality adjusted life year; SPECT, single-photon emission computed tomography. 
